Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
Induction of antitumor immunity by indomethacin
Shoshana Morecki
*
, Elena Yacovlev
, Yael Gelfand
, Victoria Trembovler
,
Esther Shohami
, Shimon Slavin
*
Corresponding author for this work
School of Pharmacy
Research output
:
Contribution to journal
›
Article
›
peer-review
27
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Induction of antitumor immunity by indomethacin'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Indomethacin
100%
Tumor Immunity
100%
Prostaglandin E2
66%
Tumor Cells
66%
Endogenic
50%
High Concentration
33%
Anti-tumor Response
33%
Carcinoma Cells
33%
Lung
16%
T Cells
16%
In Vitro Activation
16%
Tumor
16%
Cells in Culture
16%
Immunization
16%
Interleukin-2
16%
Immunomodulator
16%
White Blood Cell Count
16%
Human Tumor Cells
16%
Murine Tumors
16%
Tumor-free
16%
Syngeneic Mice
16%
Mitogenic Response
16%
Spleen Size
16%
Continuous Administration
16%
Dispensation
16%
Normal White Blood Cells
16%
4T1 Model
16%
Immunology and Microbiology
Indometacin
100%
Tumor Cell
83%
Prostaglandin E2
66%
Carcinoma Cell
33%
T Cell
16%
Immunotherapy
16%
Interleukin 2
16%
Leukocyte Count
16%
Immunomodulating Drugs
16%
Syngenic
16%
Mitogenesis
16%
Spleen Size
16%
In Vitro
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Indometacin
100%
Prostaglandin E2
66%
Carcinoma
33%
Immunotherapy
16%
Interleukin 2
16%
Immunomodulating Agent
16%